The combined use of Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) offers potential cardiometabolic benefits in type 2 diabetes mellitus. However, real-world data on this strategy, particularly in Southeast Asian populations, remains scarce. This study assessed the effectiveness of the combination versus SGLT2i or other oral antidiabetic drugs (OADs) in Indonesian patients on glycemic control and cardiorenal outcomes. A retrospective cohort study was conducted over ≥12 months among three treatment groups. Data were analyzed using the Shapiro–Wilk test for normality, followed by ANOVA or Kruskal–Wallis tests. Among the 111 patients, a notable intergroup difference was detected in systolic blood pressure (−15.8, −2.79, and −4.16 mmHg in combination, SGLT2i, and OADs group, respectively; p = 0.011) and diastolic blood pressure (−9.56, +1.06, −2.24 mmHg; p = 0.001). No significant differences were observed in HbA1c, weight, body mass index, fasting plasma glucose, lipid composites, estimated glomerular filtration rate, or atherosclerotic cardiovascular disease risk score across the groups. GLP-1 RA and SGLT2i combination therapy was associated with improved blood pressure, suggesting added cardiovascular benefit. Larger prospective studies are warranted to confirm these findings.
Cokro F, Sauriasari R, Tahapary DL, Setiawan H, Tricaesario C, Hidayati N, Soegondo S. Effectiveness of the combination of SGLT2 inhibitor and GLP-1 agonist on glycemic control and cardiorenal outcomes: A pilot real-world study in Indonesia. J Appl Pharm Sci. 2026. Article in Press. http://doi.org/10.7324/JAPS.2026.266181
1. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354-95. https://doi.org/10.4239/wjd.v7.i17.354
2. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86. https://doi.org/10.2337/dci22-0034
3. Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140-57. https://doi.org/10.2337/dc23-S009
4. Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes & Endocrinol. 2018;6(5):370-81. https://doi.org/10.1016/S2213-8587(18)30023-8
5. Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004-6. https://doi.org/10.1016/S2213-8587(16)30267-4
6. Saroka RM, Kane MP, Busch RS, Watsky J, Hamilton RA. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. Endocr Pract. 2015;21(12):1315-22. https://doi.org/10.4158/EP15877.OR
7. Goncalves E, Bell DSH. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: sequential or simultaneous start?. Diabetes Obes Metab. 2017;19(6):909-11. https://doi.org/10.1111/dom.12897
8. MSD Manual Professional Edition. Calculators: Cardiovascular Risk Assessment (10-year, Revised Pooled Cohort Equations 2018). [cited 2024 Jan 29]. Available from: https://www.msdmanuals.com/professional/multimedia/clinical-calculator/cardiovascular-risk-assessment-10-year-revised-pooled-cohort-equations-2018
9. Guo M, Gu J, Teng F, Chen J, Ma X, Chen Q, et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine. 2020;67(2):294-304. https://doi.org/10.1007/s12020-019-02175-6
10. Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis. Sci Rep. 2019;9(1):19351. https://doi.org/10.1038/s41598-019-55524-w
11. Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 2021;26(3):623-42. https://doi.org/10.1007/s10741-020-10038-w
12. Muskiet MHA, Tonneijck L, Smits MM, Van Baar MJB, Kramer MHH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605-28. https://doi.org/10.1038/nrneph.2017.123
13. Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obesity Rev. 2019;20(6):816-28. https://doi.org/10.1111/obr.12841
14. Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsa E, Stampouloglou PK, et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis. J Diabetes Res. 2018;1(1):1232583. https://doi.org/10.1155/2018/1232583
15. Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, et al. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System [Internet]. Front Endocrinol Internet. 2021;12:738848. Available from: https://doi.org/10.3389/fendo.2021.738848
16. Diallo A, Carlos-Bolumbu M, Galtier F. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2023;60(12):1651-62. https://doi.org/10.1007/s00592-023-02154-4
17. Soeatmadji DW, Rosandi R, Saraswati MR, Sibarani RP, Tarigan WO. Clinicodemographic profile and outcomes of Type 2 diabetes mellitus in the Indonesian Cohort of DISCOVER: a 3-year prospective cohort study. J ASEAN Fed Endocrine Societies. 2023;38(1):68-74.
18. Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, De Zeeuw D, et al. A Prospective cohort study in patients with type 2 diabetes mellitus for validation of biomarkers (PROVALID)-study design and baseline characteristics. Kidney Blood Press Res. 2018;43(1):181-90. https://doi.org/10.1159/000487500
19. Tran AT, Berg TJ, Gjelsvik B, Mdala I, Thue G, Cooper JG, et al. Ethnic and gender differences in the management of type 2 diabetes: a cross-sectional study from Norwegian general practice. BMC Health Serv Res. 2019;19(1):904. https://doi.org/10.1186/s12913-019-4557-4
20. Anindya K, Marthias T, Zulfikar Biruni M, Hage S, Ng N, Laverty AA, et al. Low physical activity is associated with adverse health outcome and higher costs in Indonesia: A national panel study. Front Cardiovasc Med [Internet]. 2022;9:972461. doi: https://doi.org/10.3389/fcvm.2022.972461
21. Pristyna G, Mahmudiono T, Rifqi MA, Indriani D. The relationship between Big Five Personality Traits, eating habits, physical activity, and obesity in Indonesia based on analysis of the 5th wave Indonesia Family Life Survey (2014) [Internet]. Front Psychol Internet. 2022;13:13. doi: https://doi.org/10.3389/fpsyg.2022.881436
22. Cokro F, Sauriasari R, Tahapary DL, Setiawan H, Martha E. Analysis of specialist doctors’ behavior towards SGLT2 inhibitors prescription in Indonesia: a qualitative study. Narra J. 2025;5(1):e2089. https://doi.org/10.52225/narra.v5i1.2089
23. Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, et al. Influence of the combination of SGLT2 inhibitors and GLP- 1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study. Front Pharmacol. 2024;15:1358573. https://doi.org/10.3389/fphar.2024.1358573
Year
Month